As reported in BioSpace; trials for an oral treatment to treat inflammatory bowel disease (IBD) by Morphic Therapeutics has just dosed their first healthy subjects in the Phase 1 trial. The new molecule, MORF-057, is still in clinical development and being studied to determine the oral therapies safety and effectiveness, as well as the pharmacokinetic profile. This drug, specifically targeting ulcerative colitis, is similar to an available injectable option, but the oral administration would make access and injection easier for patients.
Inflammatory Bowel Sisease
Phase 1 Trials Dosing Begins
“Based on its extensive preclinical data package, we believe that MORF-057 can selectively target the same clinically validated mechanism as the approved injectable antibody, vedolizumab, but utilizing a substantially more convenient oral small molecule.